Skip to main content
. 2019 Sep 30;12(5):629–638. doi: 10.1093/ckj/sfz127

Table 2.

Dose and administration regimens of rituximab for idiopathic membranous nephropathy

NICE [20] MENTOR [3] GEMRITUX [20] GEMRITUX [8]
Design Retrospective cohort (observational) RCT RCT RCT
N for rituximab group 28 65 27a 37
Initial rituximab dose 2 × 1 g, 2-week interval 2 × 1 g, 2-week interval 2 × 375 mg/m2, 1-week interval (total dose 1.45 g) 2 × 375 mg/m2, 1-week interval
Mean age (years) 63 52 51 53
Baseline proteinuria (g/g)b 5.9 6.2 8.4 7.7
Overall remissions 6 months, n/N (%) 18/28 (64) 23/65 (35) 8/27 (30) 13/37 (35)
Complete remission 6 months, n/N (%) 5/28 (18) 0/65 (0) 0/27 (0) No data
Overall remissions end of follow-up, n/N (%) 24/28 (86) at median 15 months 39/65 (60) at 24 months 18/27 (67) at median 24 months 24/37 (65) at median 17 months
Complete remissions end of follow-up, n/N (%) 9/28 (32) at median 15 months 23/65 (35) at 24 months

  • 6/27 (22) at median 24 months

  • No statistically significant difference versus NICE or MENTOR

  • 7/37 (19)

  • No statistically significant difference versus NICE or MENTOR

Data from clinical trials and an observational cohort. Note that age was similar for MENTOR and GEMRITUX, GFR was similar for all groups (not shown). NICE, National Institute for Health and Care Excellence.

a

Only anti-PLA2R-positive patients in this analysis.

b

For MENTOR, please note that in Table 2, proteinuria is expressed in g/g urinary creatinine but in Table 1 it is expressed in g/day.